Literature DB >> 25901316

NK cells require IL-28R for optimal in vivo activity.

Fernando Souza-Fonseca-Guimaraes1, Arabella Young1, Deepak Mittal2, Ludovic Martinet2, Claudia Bruedigam3, Kazuyoshi Takeda4, Christopher E Andoniou5, Mariapia A Degli-Esposti5, Geoffrey R Hill6, Mark J Smyth7.   

Abstract

Natural killer (NK) cells are naturally circulating innate lymphoid cells that protect against tumor initiation and metastasis and contribute to immunopathology during inflammation. The signals that prime NK cells are not completely understood, and, although the importance of IFN type I is well recognized, the role of type III IFN is comparatively very poorly studied. IL-28R-deficient mice were resistant to LPS and cecal ligation puncture-induced septic shock, and hallmark cytokines in these disease models were dysregulated in the absence of IL-28R. IL-28R-deficient mice were more sensitive to experimental tumor metastasis and carcinogen-induced tumor formation than WT mice, and additional blockade of interferon alpha/beta receptor 1 (IFNAR1), but not IFN-γ, further enhanced metastasis and tumor development. IL-28R-deficient mice were also more susceptible to growth of the NK cell-sensitive lymphoma, RMAs. Specific loss of IL-28R in NK cells transferred into lymphocyte-deficient mice resulted in reduced LPS-induced IFN-γ levels and enhanced tumor metastasis. Therefore, by using IL-28R-deficient mice, which are unable to signal type III IFN-λ, we demonstrate for the first time, to our knowledge, the ability of IFN-λ to directly regulate NK cell effector functions in vivo, alone and in the context of IFN-αβ.

Entities:  

Keywords:  IL-28R; LPS; NK cells; anti-tumor; interferon

Mesh:

Substances:

Year:  2015        PMID: 25901316      PMCID: PMC4426428          DOI: 10.1073/pnas.1424241112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  57 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

Review 2.  Natural killer (NK) cells in antibacterial innate immunity: angels or devils?

Authors:  Fernando Souza-Fonseca-Guimaraes; Minou Adib-Conquy; Jean-Marc Cavaillon
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

3.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

Authors:  S E Street; E Cretney; M J Smyth
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

Review 4.  Developmental pathways that generate natural-killer-cell diversity in mice and humans.

Authors:  Nicholas D Huntington; Christian A J Vosshenrich; James P Di Santo
Journal:  Nat Rev Immunol       Date:  2007-09       Impact factor: 53.106

5.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance.

Authors:  Xuefang Cao; Sheng F Cai; Todd A Fehniger; Jiling Song; Lynne I Collins; David R Piwnica-Worms; Timothy J Ley
Journal:  Immunity       Date:  2007-10-04       Impact factor: 31.745

6.  Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis.

Authors:  Jeremy B Swann; Matthew D Vesely; Anabel Silva; Janelle Sharkey; Shizuo Akira; Robert D Schreiber; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

7.  Immunodesign of experimental sepsis by cecal ligation and puncture.

Authors:  Daniel Rittirsch; Markus S Huber-Lang; Michael A Flierl; Peter A Ward
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 8.  Cytokine cascade in sepsis.

Authors:  Jean-Marc Cavaillon; Minou Adib-Conquy; Catherine Fitting; Christophe Adrie; Didier Payen
Journal:  Scand J Infect Dis       Date:  2003

Review 9.  Interferon lambda: a new sword in cancer immunotherapy.

Authors:  Ahmed Lasfar; Walid Abushahba; Murugabaskar Balan; Karine A Cohen-Solal
Journal:  Clin Dev Immunol       Date:  2011-12-06

10.  Adverse functions of IL-17A in experimental sepsis.

Authors:  Michael A Flierl; Daniel Rittirsch; Hongwei Gao; Laszlo M Hoesel; Brian A Nadeau; Danielle E Day; Firas S Zetoune; J Vidya Sarma; Markus S Huber-Lang; James L M Ferrara; Peter A Ward
Journal:  FASEB J       Date:  2008-02-25       Impact factor: 5.834

View more
  43 in total

Review 1.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

2.  Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.

Authors:  Eva M Putz; Camille Guillerey; Kevin Kos; Kimberley Stannard; Kim Miles; Rebecca B Delconte; Kazuyoshi Takeda; Sandra E Nicholson; Nicholas D Huntington; Mark J Smyth
Journal:  Oncoimmunology       Date:  2017-02-07       Impact factor: 8.110

3.  Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Authors:  Yulong Gao; Fernando Souza-Fonseca-Guimaraes; Tobias Bald; Susanna S Ng; Arabella Young; Shin Foong Ngiow; Jai Rautela; Jasmin Straube; Nic Waddell; Stephen J Blake; Juming Yan; Laurent Bartholin; Jason S Lee; Eric Vivier; Kazuyoshi Takeda; Meriem Messaoudene; Laurence Zitvogel; Michele W L Teng; Gabrielle T Belz; Christian R Engwerda; Nicholas D Huntington; Kyohei Nakamura; Michael Hölzel; Mark J Smyth
Journal:  Nat Immunol       Date:  2017-07-31       Impact factor: 25.606

4.  IFN-λ suppresses intestinal inflammation by non-translational regulation of neutrophil function.

Authors:  Achille Broggi; Yunhao Tan; Francesca Granucci; Ivan Zanoni
Journal:  Nat Immunol       Date:  2017-08-28       Impact factor: 25.606

5.  Defective natural killer cell activity in a mouse model of eczema herpeticum.

Authors:  Yuko Kawakami; Tomoaki Ando; Jong-Rok Lee; Gisen Kim; Yu Kawakami; Tae Nakasaki; Manando Nakasaki; Kenji Matsumoto; Youn Soo Choi; Toshiaki Kawakami
Journal:  J Allergy Clin Immunol       Date:  2016-07-29       Impact factor: 10.793

Review 6.  Shared and Distinct Functions of Type I and Type III Interferons.

Authors:  Helen M Lazear; John W Schoggins; Michael S Diamond
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

7.  Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.

Authors:  Fernando Souza-Fonseca-Guimaraes; Stephen J Blake; Amani Makkouk; Cariad Chester; Holbrook E Kohrt; Mark J Smyth
Journal:  Oncoimmunology       Date:  2016-06-30       Impact factor: 8.110

Review 8.  IFN-λ cancer immunotherapy: new kid on the block.

Authors:  Ahmed Lasfar; Helen Gogas; Andrew Zloza; Howard L Kaufman; John M Kirkwood
Journal:  Immunotherapy       Date:  2016-07       Impact factor: 4.196

Review 9.  Interferon-λ orchestrates innate and adaptive mucosal immune responses.

Authors:  Liang Ye; Daniel Schnepf; Peter Staeheli
Journal:  Nat Rev Immunol       Date:  2019-06-14       Impact factor: 53.106

Review 10.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.